Oruka Therapeutics Inc Dossier - Source-backed chat

Oruka Therapeutics Inc

ORKANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.20

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $83.42Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $5.5B

Enterprise Value $5.3B

Shares Outstanding 66.2M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Oruka Therapeutics is a clinical-stage biotechnology company positioned to disrupt the multi-billion dollar psoriasis and immunology market. By applying advanced antibody engineering to validated mechanisms of action (IL-23p19 and IL-17A/F), Oruka is developing potentially best-in-class biologics (ORKA-001 and ORKA-002) designed to deliver complete disease clearance with highly infrequent dosing (once or twice a year). Positive interim Phase 2a data for ORKA-001 (63.5% PASI 100 at Week 16) and strong Phase 1 PK data (100-day half-life) validate this approach. Backed by a robust cash position of $496 million as of Q1 2026 and a transformative $700 million upsized public offering in April 2026, the company has a secure financial runway extending through its anticipated BLA filing for ORKA-001.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$102.00

Mean target$153.75

High · most bullish analyst$200.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$102.00

Longer-term follow-up data (Week 28/52) for ORKA-001 reveals a faster-than-expected decline in efficacy or unexpected late-emerging safety concerns, undermining the annual dosing thesis. Competitors launch next-generation therapies that close the durability gap, or clinical trial delays extend the development timeline, forcing additional dilutive capital raises and depressing the stock toward the low-end target of $45.00.

Base CaseCentral scenario

$153.75

Matches the consensus mean

ORKA-001 maintains its strong efficacy profile (PASI 100 >60%) in the ongoing EVERLAST-B Phase 2b trial, with data in 2027 supporting a smooth transition into Phase 3. ORKA-002 successfully advances through its Phase 2 trials in psoriasis and hidradenitis suppurativa. The company's cash runway remains sufficient to reach key clinical milestones without premature dilutive financing, aligning with the consensus analyst price target of approximately $142.17.

Bull CaseUpside scenario

$200.00

ORKA-001 and ORKA-002 demonstrate superior long-term durability in Phase 2b/3 trials, confirming the potential for annual or semi-annual dosing. The Halozyme Hypercon collaboration successfully delivers a highly concentrated, low-volume formulation that enhances patient convenience. Rapid market adoption post-approval allows Oruka to capture significant market share from established daily or monthly therapies, driving the stock toward the high-end analyst target of $200.00.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Compelling interim Phase 2a data for ORKA-001 showing 63.5% PASI 100, 83% PASI 90, and 84% IGA 0/1 at Week 16, matching or exceeding historical benchmarks of leading IL-23 inhibitors.
Extended half-life technology (100 days for ORKA-001 and 75-80 days for ORKA-002) supporting potential once-yearly dosing for psoriasis and quarterly dosing for hidradenitis suppurativa.
Exceptional balance sheet strength with $496 million in cash and marketable securities as of March 31, 2026, further bolstered by a $700 million upsized public offering in April 2026.
Strategic global collaboration with Halozyme to utilize Hypercon technology, enabling hyperconcentration and low-volume, patient-friendly administration of ORKA-001.

Key Investment Risks

Clinical development risk inherent to early-stage biopharmaceutical companies, with lead assets still in Phase 2 testing.
Intense competition in the immunology and dermatology space from established pharmaceutical giants (e.g., AbbVie's Skyrizi, J&J's Tremfya) and other emerging biotech players.
Regulatory hurdles and potential delays in securing FDA approval or BLA filings.
Dependence on third-party partners (such as Paragon Therapeutics and Halozyme) for antibody engineering and formulation technologies.

Thesis Invalidation Triggers

Failure of ORKA-001 to meet its primary endpoint of PASI 100 at Week 16 in the Phase 2b EVERLAST-B trial.
A significant drop in the duration of response in the 52-week follow-up of EVERLAST-A, invalidating the annual dosing hypothesis.
Emergence of serious, class-disrupting adverse events in the clinical trials of ORKA-001 or ORKA-002.
Unexpected regulatory roadblocks or clinical holds imposed by the FDA on Oruka's development programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.